|
|
|
| Effects of TFPI-2 on Proliferation, Apoptosis and AFP Expression of Hepatocarcinoma Cells |
| QIN Xiao-lin1, XU Yong2, FAN Xiao-qing1, LI Wu-xian1, KUANG Wen-bin1, CHENG eng1, TU Zhi-guang1 |
1. Key Laboratory of Laboratory Medical Diagnostics of Education Ministry, Chongqing Medical University, Chongqing 400016, China;
2. Pingshan People's Hospital, Shenzhen 518118, China |
|
|
|
Abstract Objective: To investigate the effects of tissue factor pathway inhibitor-2 (TFPI-2) gene on the proliferation, apoptosis and expression of alpha fetoprotein of hepatocarcinoma cell line Hep3B. Methods: The recombinant vector of PCDNA3.1-TFPI-2 was transfected into Hep3B cells with liposome, and the cells were selected by G418. The expressions of TFPI-2 mRNA and protein were detected by RT-PCR and Western blot respectively. The influence of TFPI-2 on the proliferation of Hep3B cells via growth curve was assayed by CCK-8 method. The colony-forming unit assay was used to measure single cell self-replication ability. The expression of AFP mRNA was detected by RT-PCR and the AFP secretion of Hep3B cell was measured by electro-chemiluminescence (ECL) immunoassay. Furthermore, the apoptosis was tested by flow cytometry. Results: Expressions of mRNA and protein of TFPI-2 were identified in cells transfected by PCDNA3.1-TFPI-2. The growth rate and self-replication ability of Hep3B cells were significantly lower than those of the two control groups. The inhibition ratio of AFP mRNA expression was 16.51%, and the AFP secretion of Hep3B cells transfected with PCDNA3.1-TFPI-2 was significantly lower than the control groups (P<0.01). The rate of early apoptosis was significantly increased (24.03%±7.28% vs 8.77%±3.66%). Conclusions: The expression of TFPI-2 can simultaneously inhibit the growth and expression of AFP of hepatocarcinoma cells as well as induce early apoptosis.
|
|
Received: 09 August 2011
Published: 25 December 2011
|
|
|
|
|
|
[1] Okuda K. Hepatocellular carcinoma: recent progress. Hepatology, 1992,15(5):948-963.
[2] Enzan H, Himeno H, Iwamura S, et al. Alpha-smooth muscle actin-positive perisinusoidal stromal cells in human hepatocellular carcinoma. Hepatology, 1994,19(4):895-903.
[3] Faouzi S, Le Bail B, Neaud V, et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol, 1999,30(2):275-284.
[4] Terada T, Makimoto K, Terayama N, et al. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol, 1996,24(6):706-712.
[5] Neaud V, Duplantier J G, Mazzocco C, et al. Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism. J Biol Chem, 2004,279(7):5200-5206.
[6] 周金敬, 徐勇, 涂植光. Tfpi-2在肝癌和正常肝组织中表达的差异. 重庆医科大学学报, 2009,11:1472-1474. Zhou J J, Xu Y, Tu Z G. Journal of Chongqing Medical University, 2009, 11:1472-1474.
[7] Yong X, Xiaolin Q, Jinjing Z H, et al. Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma. Oncology Letters, 2011,2(5):779-783.
[8] 毕晓, 徐勇, 涂植光, 等. 中国人组织因子途径抑制物-2基因的真核表达载体的构建. 国际检验医学杂志, 2007,28(2):106-107. Bi X, Xu Y, Tu Z G. Int J Lab Med, 2007,28(2):106-107.
[9] 徐勇, 刘雪燕, 李体远, 等. 中国人tfpi-2基因的克隆及测序分析.国外医学《临床生物化学与检验学分册》, 2005,26(7):388-392. Xu Y, Liu X Y, Li T Y, et al. Cin Biochem & Lab Med Foreign Med Sci, 2005,26(7):388-392.
[10] Kong D, Ma D, Bai H, et al. Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2. Biochem Biophys Res Commun, 2004,324(4):1179-1185.
[11] 仲任, 宋善俊. 组织因子途径抑制物2诱导人卵巢癌a2780细胞凋亡及其机制研究. 华中科技大学学报《医学版》, 2010,39(5):635-638. Zhong R, Song S J. Acta Med Univ Sci Technol Huazhong, 2010,39(5):635-638.
[12] Kondraganti S, Gondi C S, Gujrati M, et al. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol, 2006,29(1):25-32.
[13] 汤志刚, 孙振阳, 胡何节, 等. Tfpi-2对胰腺癌细胞体内和体外侵袭能力的影响. 中国普外基础与临床杂志, 2008,01:46-50. Tang Z G, Sun Z Y, Hu H T, et al. Chin J Base Clin General Surg, 2008,01:46-50.
[14] 仲任, 黄瑞滨, 宋善俊, 等. 组织因子途径抑制物2对卵巢癌细胞迁徙和浸润能力的影响.中德临床肿瘤学杂志《英文版》, 2005,4(1):53-55. Zhong R, Huang R B, Song S J, et al. The Chinese-German Journal of Clinical Oncology, 2005,4(1):53-55.
[15] Yanamandra N, Kondraganti S, Gondi C S, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer, 2005,115(6):998-1005.
[16] Rollin J, Iochmann S, Blechet C, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer, 2005,92(4):775-783.
[17] 汤志刚, 孙振阳, 胡何节, 等. Tfpi-2基因克隆及其在胰腺癌细胞中的表达. 肿瘤防治研究, 2008,01:5-7. Tang Z G, Sun Z Y, Hu H J, et al. Cancer Research on Prevention and Treatment, 2008,01:5-7.
[18] 董永强, 纪涛, 张晓明, 等. 组织因子途径抑制物-2在非小细胞肺癌中的表达及其与细胞凋亡的关系. 实用医学杂志, 2010,11:1903-1905. Dong Y Q, Ji T, Zhang X M, et al. The Journal of Practical Medicine, 2010,11:1903-1905.
[19] 孙振阳, 汤志刚, 胡何节,等. 胰腺癌tfpi-2蛋白表达与细胞凋亡. 现代肿瘤医学, 2008,04:586-588. Sun Z Y, Tang Z G, Hu H J, et al. Modern Oncology, 2008,04:586-588.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
